Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.

@article{Conte2009MulticenterPI,
  title={Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.},
  author={Michael S. Conte and Helen M Nugent and Peter Gaccione and Indira Guleria and Prabir T Roy-Chaudhury and Jeffrey Harold Lawson},
  journal={Journal of vascular surgery},
  year={2009},
  volume={50 6},
  pages={
          1359-68.e1
        }
}
OBJECTIVES Vascular access dysfunction is the major cause of morbidity in patients on hemodialysis to treat end stage renal disease. Preclinical studies have demonstrated that the perivascular placement of implants containing allogeneic aortic endothelial cells (Vascugel) reduces thrombosis, inflammation, stenosis and increases lumen diameter in porcine models of arteriovenous fistulae (AVF) and arteriovenous grafts (AVG). We conducted a phase I/II clinical study to investigate the safety of… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Bioengineered vascular grafts: can we make them off-the-shelf?

Trends in cardiovascular medicine • 2011
View 6 Excerpts
Highly Influenced

Matrix-embedded endothelial cells are protected from the uremic milieu.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2011
View 8 Excerpts
Highly Influenced

New Developments in Our Understanding of Neointimal Hyperplasia

Advances in chronic kidney disease • 2015
View 4 Excerpts
Highly Influenced